NYSE:HAE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	1,604	287	301	N/A	5
3/31/2026	1,475	217	253	N/A	7
3/31/2025	1,400	153	290	N/A	7
3/30/2024	1,309	118	115	182	N/A
12/30/2023	1,270	127	129	197	N/A
9/30/2023	1,239	128	199	262	N/A
7/1/2023	1,219	137	176	250	N/A
4/1/2023	1,169	115	163	273	N/A
12/31/2022	1,129	96	128	261	N/A
10/1/2022	1,084	86	116	260	N/A
7/2/2022	1,026	68	88	216	N/A
4/2/2022	993	43	76	172	N/A
1/1/2022	953	23	33	106	N/A
10/2/2021	934	31	54	110	N/A
7/3/2021	903	64	52	95	N/A
4/3/2021	870	79	72	109	N/A
12/26/2020	884	108	118	154	N/A
9/26/2020	903	106	120	167	N/A
6/27/2020	946	96	119	167	N/A
3/28/2020	988	77	109	158	N/A
12/28/2019	999	80	81	132	N/A
9/28/2019	988	68	51	111	N/A
6/29/2019	977	49	39	139	N/A
3/30/2019	968	55	40	159	N/A
12/29/2018	952	46	72	196	N/A
9/29/2018	939	21	82	204	N/A
6/30/2018	922	23	116	205	N/A
3/31/2018	904	46	146	220	N/A
12/30/2017	898	-17	N/A	197	N/A
9/30/2017	892	4	N/A	187	N/A
7/1/2017	887	4	N/A	167	N/A
4/1/2017	886	-26	N/A	160	N/A
12/31/2016	900	16	N/A	178	N/A
10/1/2016	906	-59	N/A	155	N/A
7/2/2016	905	-66	N/A	143	N/A
4/2/2016	909	-56	N/A	122	N/A
12/26/2015	893	-50	N/A	124	N/A
9/26/2015	891	26	N/A	119	N/A
6/27/2015	899	20	N/A	123	N/A
3/28/2015	910	17	N/A	127	N/A
12/27/2014	925	30	N/A	123	N/A
9/27/2014	935	30	N/A	142	N/A
6/28/2014	943	39	N/A	140	N/A
3/29/2014	939	35	N/A	140	N/A
12/28/2013	947	38	N/A	116	N/A
9/28/2013	953	31	N/A	94	N/A
6/29/2013	935	21	N/A	98	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HAEの予測収益成長率 (年間28.1% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: HAEの収益 ( 28.1% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: HAEの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: HAEの収益 ( 8.1% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: HAEの収益 ( 8.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HAEの自己資本利益率は、3年後には低くなると予測されています ( 19.9 %)。

Haemonetics 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Price target increased by 8.3% to US$109

Consensus EPS estimates increase by 25%

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Recent updates

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device

CEO, President & Director exercised options and sold US$3.3m worth of stock

Haemonetics Corporation, Annual General Meeting, Jul 25, 2024

Executive VP notifies of intention to sell stock

New minor risk - Earnings quality

New minor risk - Earnings quality

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025

Full year 2024 earnings released: EPS: US$2.32 (vs US$2.27 in FY 2023)

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation to Report Q4, 2024 Results on May 09, 2024

Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation (NYSE:HAE) completed the acquisition of Advanced Cooling Therapy, Inc.

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Haemonetics Corporation (NYSE:HAE) has entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for $160 million.

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation to Report Q3, 2024 Results on Feb 08, 2024

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics: Solid Performance Of This Blood Play

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

Haemonetics Corporation to Report Q2, 2024 Results on Nov 02, 2023

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$109

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Insider notifies of intention to sell stock

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

CEO, President & Director exercised options and sold US$6.6m worth of stock

Haemonetics Corporation Receives FDA Clearance for Enhancements to NexSys PCS(R) Plasma Collection System

Haemonetics Corporation, Annual General Meeting, Aug 04, 2023

Executive VP & CTO recently sold US$192k worth of stock

Consensus EPS estimates increase by 25%

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Full year 2023 earnings released: EPS: US$2.27 (vs US$0.85 in FY 2022)

Insufficient new directors

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Haemonetics Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Insider notifies of intention to sell stock

Investor sentiment improved over the past week

Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Price target increased to US$95.29

Price target increased to US$93.57

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics Corporation Updates Revenue Guidance for the Year 2023

Haemonetics Q2 2023 Earnings Preview

Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer

Now 20% undervalued